Accuray (NSDQ:ARAY) said it inked a deal with RaySearch Laboratories to allow Accuray to co-market RaySearch’s RayCare oncology information system in several designated major radiation therapy markets RayCare is designed to handle logistical challenges present in modern radiation therapy centers by using high-performance radiation therapy algorithms, Sunnyvale, Calif.-based Accuray said. “In today’s complex healthcare environment it is […]
Accuray Inc.
GPO: Accuray lands 3-year contract with Premier
Accuray settles patent infringement, poaching spat with Best Medical
Silicon Valley in-depth: Tapping medtech’s Big Data with AliveCor CEO Euan Thomson
Teleflex announces plans to cut costs and streamline manufacturing | Medtech Wall Street news for the week of May 5, 2014
Morgan Stanley: Medtech underperformed in April
The medical device sector under-performed the S&P 500 index in April after a sharp swing over-performance during the 1st quarter, according to analysts at Morgan Stanley.
The 30 medtech stocks Morgan Stanley covers collectively under-performed the S&P by 4.1%, after besting the index by 4.9% during the 1st quarter.
Revenue surge helps Accuray narrow Q3 losses, update full-year outlook
Accuray notches win in trade secrets row with former supplier
Accuray soars on Street-beating Q2 and increased guidance
Accuray gains on Q1 results
Accuray (NSDQ:ARAY) shares gained nearly 10% this morning after the medical device company reported lower fiscal 1st-quarter losses and an improved profit margin.
Sunnyvale, Calif.-based Accuray logged losses of $15.5 million, or -21¢ per share, on sales of $76.6 million for the 3 months ended Sept. 30, for a loss reduction of 35.6% on a sales decline of 7.4%.